Phase 3 Non-alcoholic Fatty Liver Clinical Trials
2 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,250 enrolled43 locationsNCT07221188
Recruiting
Phase 3
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,200 enrolled49 locationsNCT07221227